Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Why Viking Therapeutics Stock Plummeted After Soaring Today

Viking Therapeutics (VKTX) shares fell Monday, handing back early gains, as analysts questioned the path ahead for its developmental weight-loss drugs even after news of upbeat results in clinical trials.

Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results

Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell the news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025.

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics (NASDAQ:VKTX) shares jumped then fell after it reported results from a trial of its weightloss tablet.  The San Diego company said its phase-one clinical trial of an oral tablet formulation of its VK2735 tablet dosed daily for 28 days resulted in up to 8.2% mean weight loss for some patients, or 6.8% versus a placebo.

Viking Therapeutics reports encouraging results from weightloss tablet

Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 4.3% to trade at $74.13 at last glance, reversing course from earlier gains.

Biotech Stock Reverses Gains Despite Obesity Pill Buzz

Viking Therapeutics Inc VKTX announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024.

Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety

Viking Therapeutics (NASDAQ: VKTX) saw its stock surge over 10% in pre-market trading on November 4, following the release of highly encouraging early-stage results for its experimental obesity drug, VK2735. In a study presented at the ObesityWeek conference, patients taking a 100 mg dose of VK2735 lost an average of 8.

Should you buy Viking Therapeutics (VKTX) after today's spike?

Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations.

Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations

Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735  Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile  Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Dosing Regimen SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek® 2024, the annual meeting of the Obesity Society.  VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders.

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.

Viking Therapeutics stock jumps after ‘great' trial of weight-loss drug

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.. The post Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data appeared first on Investor's Business Daily.

Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data

SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences.  Details of the company's participation are as follows: Truist Healthcare Conference Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: November 7, 2024 Fireside Chat Timing: 12:30 – 1:00 p.m.

Viking Therapeutics to Participate at Upcoming Investor Conferences

It might not be too late to get in on the party.

This High-Flying Stock Just Became a Better Buy

Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate VK2735 dosages and start Phase 2 trials, with Phase 3 trials for the injectable version and VK2809 NASH drug also in the pipeline. The stock has a market cap below $9 billion while larger competitors have seen stock valuations soar by multiples of these levels indicating the opportunity for Viking Therapeutics.

Viking Therapeutics: Lots Of Positives

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO , Oct. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that clinical data from the company's VK2735 obesity program will be highlighted in two poster presentations at ObesityWeek® 2024, the annual meeting of the Obesity Society.  VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders.

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?

Viking Therapeutics shows significant clinical progress in obesity, NASH, and X-ALD, with promising Phase II and preclinical data positioning it for potential market leadership. Despite operating at a loss, Viking maintains a strong cash position to support aggressive R&D, with Q3 financials reflecting increased expenses but sufficient liquidity. Upcoming catalysts, including Phase III trials for VK2735 and oral VK2735 studies, could significantly impact Viking's market value and competitive positioning.

Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts

Capri Holdings Ltd

US benchmark equity averages rose on Friday as the market ended a three-day losing streak.  At the time of writing, the Dow Jones Industrial Average was up 0.3%, while S&P 500 rose 0.8% from the previous close.

S&P 500, Nasdaq rise sharply ending 3-day losing streak; Viking Therapeutics surge, while Capri's shares slump

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday

Intellia Therapeutics

The ever-volatile biotech sector is making noise today.

2 Biotech Stocks Making Big Moves

Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings that showed enough cash on its balance sheet to fund key clinical trials.

Viking Therapeutics' stock soars 18% as data on oral weight-loss drug looms

Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.

VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2024 Earnings Conference Call October 23, 2024 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Joon Lee – Truist Annabel Samimy – Stifel Steve Seedhouse – Raymond James Roger Song – Jefferies Jay Olson – Oppenheimer Justin Zelin – BTIG Thomas Smith – Leerink Partners Yale Jen – Laidlaw & Company Hardik Parikh – JPMorgan Alex Ramsey – William Blair Operator Welcome to the Viking Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all parties are in a listen-only mode.

News for Viking Therapeutics Stock (VKTX)